Loading

Our Team

Developing Innovative Drugs and Drug Combinations to Improve Clinical Outcomes in Advanced Cancer

Research Portfolio

Monopar Therapeutics

Monopar Therapeutics is an emerging biopharmaceutical company focused on developing innovative drugs and drug combinations to improve clinical outcomes for cancer patients. Monopar currently has three compounds in development: Validive® (clonidine mucobuccal tablet; clonidine MBT), a Phase 3-ready molecule for the prevention and treatment of severe oral mucositis (SOM) in patients undergoing radiotherapy for oropharyngeal cancer (OPC); MNPR-201 (formerly GPX-150), a novel doxorubicin analog engineered to eliminate the cardiotoxic side effects typically generated by anthracycline-based cancer drugs; and MNPR-101 (formerly huATN-658), a novel first-in-class humanized monoclonal antibody to the urokinase plasminogen activator receptor (uPAR) for the treatment of advanced cancers.
Monopar's team is located in San Francisco, CA, and Chicago, IL.

Innovative Drugs and Drug Combinations

Licensing, developing and commercializing transformative oncology therapeutics

Why Oncology?

Multiple factors drive our passion for oncology

Market Demand

The numbers behind our research define the Validive opportunity

Investment Opportunities

Monopar's team has developed and executed efficient and successful launch and commercialization strategies for multiple drug product approvals in the U.S. and EU.

Our Research Pipeline

Validive® (clonidine mucobuccal tablet; clonidine MBT) is a Phase 3-ready molecule for the prevention and treatment of severe oral mucositis (SOM) in patients undergoing radiotherapy for oropharyngeal cancer (OPC). MNPR-201 (formerly GPX-150) is a novel doxorubicin analog engineered to eliminate the cardiotoxic side effects typically generated by anthracycline-based cancer drugs. MNPR-101 (formerly huATN-658) is a novel first-in-class humanized monoclonal antibody to the urokinase plasminogen activator receptor (uPAR) for the treatment of advanced cancers.

Indications Discovery Preclinical Phase 1 Phase 2 Phase 3

Validive®

Severe Oral Mocositis in OPC

Completed randomized placebo-controlled 183 patient Phase 2 trial for the
prevention and treatment of sever oral mocositis with encouraging results
Completed randomized placebo-controlled 183 patient Phase 2 trial for the
prevention and treatment of sever oral mocositis with encouraging results

Discovery complete

Completed randomized placebo-controlled 183 patient Phase 2 trial for the
prevention and treatment of sever oral mocositis with encouraging results
Completed randomized placebo-controlled 183 patient Phase 2 trial for the
prevention and treatment of sever oral mocositis with encouraging results

Preclinical complete

Completed randomized placebo-controlled 183 patient Phase 2 trial for the
prevention and treatment of sever oral mocositis with encouraging results
Completed randomized placebo-controlled 183 patient Phase 2 trial for the
prevention and treatment of sever oral mocositis with encouraging results

Phase 1 complete

Completed randomized placebo-controlled 183 patient Phase 2 trial for the
prevention and treatment of sever oral mocositis with encouraging results
Completed randomized placebo-controlled 183 patient Phase 2 trial for the
prevention and treatment of sever oral mocositis with encouraging results

Phase 2 in progress

Completed randomized placebo-controlled 183 patient Phase 2 trial for the
prevention and treatment of sever oral mocositis with encouraging results
Completed randomized placebo-controlled 183 patient Phase 2 trial for the
prevention and treatment of sever oral mocositis with encouraging results

Phase 3 not started

Indications Discovery Preclinical Phase 1 Phase 2 Phase 3

MNPR-201

Analog of Doxorubicin

Phase 2 data in sarcoma shows preliminary activity
and no evidence of irreversible cardiotoxicity
Phase 2 data in sarcoma shows preliminary activity
and no evidence of irreversible cardiotoxicity

Discovery complete

Phase 2 data in sarcoma shows preliminary activity
and no evidence of irreversible cardiotoxicity
Phase 2 data in sarcoma shows preliminary activity
and no evidence of irreversible cardiotoxicity

Preclinical complete

Phase 2 data in sarcoma shows preliminary activity
and no evidence of irreversible cardiotoxicity
Phase 2 data in sarcoma shows preliminary activity
and no evidence of irreversible cardiotoxicity

Phase 1 in progress

Phase 2 data in sarcoma shows preliminary activity
and no evidence of irreversible cardiotoxicity
Phase 2 data in sarcoma shows preliminary activity
and no evidence of irreversible cardiotoxicity

Phase 2 not started

Phase 2 data in sarcoma shows preliminary activity
and no evidence of irreversible cardiotoxicity
Phase 2 data in sarcoma shows preliminary activity
and no evidence of irreversible cardiotoxicity

Phase 3 not started

Indications Discovery Preclinical Phase 1 Phase 2 Phase 3

MNPR-101

Combination treatment in intractable cancers

Pre-IND Pre-IND

Discovery complete

Pre-IND Pre-IND

Preclinical in progress

Pre-IND Pre-IND

Phase 1 not started

Pre-IND Pre-IND

Phase 2 not started

Pre-IND Pre-IND

Phase 3 not started